This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will MacroGenics (MGNX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?
by Zacks Equity Research
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
by Zacks Equity Research
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 28.26% and 77.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down
by Zacks Equity Research
ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: MacroGenics (MGNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
ImmunoGen (IMGN) Q1 Earnings and Sales Miss, Shares Down
by Zacks Equity Research
ImmunoGen (IMGN) reports dismal first-quarter results.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 12.68% and 134.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Product Stocks Likely to Beat This Earnings Season
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
by Zacks Equity Research
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
Implied Volatility Surging for MacroGenics (MGNX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Frontier Communications' (FTR) Q4 Earnings: What's in Store?
by Zacks Equity Research
Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
by Zacks Equity Research
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
by Zacks Equity Research
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.